Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Issued (2016 - 2025)

Historic Shares Issued for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $445.6 million.

  • Ocular Therapeutix's Shares Issued changed N/A to $445.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $539.6 million, marking a year-over-year increase of 7056.42%. This contributed to the annual value of $539.6 million for FY2025, which is 7056.42% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Shares Issued stood at $445.6 million.
  • In the past 5 years, Ocular Therapeutix's Shares Issued ranged from a high of $445.6 million in Q4 2025 and a low of $32000.0 during Q3 2022
  • In the last 5 years, Ocular Therapeutix's Shares Issued had a median value of $693500.0 in 2021 and averaged $61.0 million.
  • Its Shares Issued has fluctuated over the past 5 years, first tumbled by 9989.38% in 2021, then surged by 40548076.92% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Shares Issued (Quarter) stood at $172000.0 in 2021, then skyrocketed by 147.67% to $426000.0 in 2022, then skyrocketed by 25188.5% to $107.7 million in 2023, then skyrocketed by 193.66% to $316.4 million in 2024, then skyrocketed by 40.84% to $445.6 million in 2025.
  • Its Shares Issued was $445.6 million in Q4 2025, compared to $89.8 million in Q2 2025 and $4.2 million in Q1 2025.